HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lajos Pusztai Selected Research

N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)

2/2021Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
11/2020Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lajos Pusztai Research Topics

Disease

235Breast Neoplasms (Breast Cancer)
03/2022 - 04/2002
194Neoplasms (Cancer)
11/2022 - 11/2002
46Pathologic Complete Response
12/2021 - 06/2005
36Triple Negative Breast Neoplasms
10/2022 - 03/2008
16Residual Neoplasm
01/2022 - 04/2004
16Neoplasm Metastasis (Metastasis)
01/2022 - 07/2004
6Disease Progression
01/2020 - 03/2006
5Carcinoma (Carcinomatosis)
10/2015 - 04/2004
3Inflammatory Breast Neoplasms
11/2013 - 02/2011
2Weight Loss (Weight Reduction)
03/2022 - 07/2018
2Circulating Neoplastic Cells
01/2022 - 04/2009
2Melanoma (Melanoma, Malignant)
10/2021 - 01/2012
2Lung Neoplasms (Lung Cancer)
01/2021 - 01/2020
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 10/2004
2Cardiotoxicity
07/2019 - 04/2018
2Obesity
07/2018 - 07/2014

Drug/Important Bio-Agent (IBA)

55Estrogen ReceptorsIBA
01/2022 - 03/2003
42Biomarkers (Surrogate Marker)IBA
03/2022 - 01/2003
38Hormones (Hormone)IBA
01/2022 - 09/2003
31Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 04/2003
29Paclitaxel (Taxol)FDA LinkGeneric
10/2022 - 02/2004
28Proteins (Proteins, Gene)FDA Link
11/2022 - 01/2003
28Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 01/2003
27Trastuzumab (Herceptin)FDA Link
11/2021 - 04/2002
22AnthracyclinesIBA
12/2021 - 04/2004
19human ERBB2 proteinIBA
01/2022 - 06/2005
18RNA (Ribonucleic Acid)IBA
09/2021 - 06/2003
18DNA (Deoxyribonucleic Acid)IBA
12/2018 - 12/2006
18Fluorouracil (Carac)FDA LinkGeneric
06/2018 - 04/2003
16Pharmaceutical PreparationsIBA
01/2022 - 07/2004
16Messenger RNA (mRNA)IBA
01/2022 - 06/2005
15taxaneIBA
12/2021 - 08/2005
13Biological ProductsIBA
10/2021 - 09/2006
11ParaffinIBA
02/2021 - 01/2003
10Epirubicin (Ellence)FDA LinkGeneric
10/2022 - 06/2005
10ErbB Receptors (EGF Receptor)IBA
11/2020 - 04/2004
9Immune Checkpoint InhibitorsIBA
01/2022 - 01/2016
9Estrogens (Estrogen)FDA Link
07/2021 - 07/2003
9TamoxifenFDA LinkGeneric
03/2018 - 04/2007
8Lapatinib (GW572016)FDA Link
10/2021 - 11/2005
8B7-H1 AntigenIBA
10/2021 - 05/2014
7pembrolizumabIBA
10/2022 - 01/2016
7durvalumabIBA
02/2022 - 10/2020
7Formaldehyde (Formol)FDA Link
02/2021 - 05/2008
7MicroRNAs (MicroRNA)IBA
02/2020 - 08/2010
7Phenobarbital (Luminal)FDA Link
03/2018 - 08/2005
6Monoclonal AntibodiesIBA
01/2019 - 04/2004
6Progesterone Receptors (Progesterone Receptor)IBA
12/2015 - 03/2008
5Tumor Biomarkers (Tumor Markers)IBA
10/2021 - 05/2008
5Capecitabine (Xeloda)FDA Link
01/2021 - 09/2003
5Phosphotransferases (Kinase)IBA
09/2015 - 11/2010
5Docetaxel (Taxotere)FDA Link
11/2012 - 04/2002
4130-nm albumin-bound paclitaxelIBA
02/2022 - 01/2018
4EverolimusFDA Link
01/2022 - 07/2014
4Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2021 - 05/2014
4Small Interfering RNA (siRNA)IBA
10/2019 - 11/2010
4Transcription Factors (Transcription Factor)IBA
07/2018 - 09/2003
4Investigational DrugsIBA
05/2018 - 07/2012
4Taxoids (Taxanes)IBA
01/2017 - 07/2004
3Carboplatin (JM8)FDA LinkGeneric
10/2022 - 07/2016
3CytokinesIBA
01/2022 - 02/2004
3Epidermal Growth Factor (EGF)IBA
01/2022 - 08/2010
3Metformin (Glucophage)FDA LinkGeneric
10/2021 - 08/2011
3atezolizumabIBA
10/2021 - 01/2016
3NucleotidesIBA
01/2021 - 01/2015
3Ado-Trastuzumab EmtansineIBA
01/2021 - 10/2016
3exemestane (Aromasin)FDA Link
01/2021 - 07/2015
3Bevacizumab (Avastin)FDA Link
01/2020 - 10/2004
3AntibodiesIBA
01/2016 - 07/2011
3Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
10/2015 - 06/2005
3Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
05/2014 - 01/2008
3Complementary DNA (cDNA)IBA
01/2006 - 03/2003
3Peptide Hydrolases (Proteases)FDA Link
03/2004 - 03/2003
22- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA
01/2022 - 12/2015
2Fulvestrant (Faslodex)FDA Link
01/2022 - 01/2018
2Circulating Tumor DNAIBA
01/2022 - 01/2022
2ChromatinIBA
01/2022 - 09/2020
2CateninsIBA
01/2022 - 08/2010
2Peptides (Polypeptides)IBA
10/2021 - 01/2008
2N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)IBA
02/2021 - 11/2020
2LigandsIBA
01/2021 - 12/2009
2Cyclin-Dependent Kinases (cdk Proteins)IBA
11/2020 - 01/2013
2Keratins (Keratin)IBA
10/2020 - 01/2016
2Fatty Acids (Saturated Fatty Acids)IBA
12/2019 - 02/2012
2Interleukin-8 (Interleukin 8)IBA
10/2019 - 01/2013
2Matrix Metalloproteinase 9 (Gelatinase B)IBA
12/2018 - 11/2009
2pertuzumabIBA
06/2018 - 10/2016
2PlatinumIBA
01/2017 - 01/2015

Therapy/Procedure

110Therapeutics
10/2022 - 04/2002
98Drug Therapy (Chemotherapy)
10/2022 - 11/2002
71Neoadjuvant Therapy
10/2022 - 11/2002
14Adjuvant Chemotherapy
01/2020 - 02/2004
10Immunotherapy
10/2021 - 01/2015
7Segmental Mastectomy (Lumpectomy)
12/2017 - 10/2006
4Mastectomy (Mammectomy)
12/2021 - 04/2011
4Aftercare (After-Treatment)
09/2020 - 11/2002
4Precision Medicine
12/2018 - 11/2006
3Combination Drug Therapy (Combination Chemotherapy)
01/2012 - 01/2010
2Radiotherapy
12/2017 - 08/2004
2Chemoprevention
01/2016 - 01/2006